Figure 3.

Anticancer effects of engineered ClyA-expressing bacteria in subcutaneous cancer models

Nude mice were implanted subcutaneously with AsPC-1 (A–D, n = 12 mice per group) or Capan-2 (E–H, n = 10 mice per group) cancer cells. When the tumor reached 100–120 mm³, mice were treated with 3.0 × 10⁷ CFU engineered bacteria (SL^lux or SL^lux/ClyA, indicated by an arrow). (A) Average tumor growth in the AsPC-1 cancer model. (B–D) AsPC-1 tumors were treated with PBS (B), engineered SL^lux (C), or SL^lux/ClyA (D). (E) Average tumor growth in the Capan-2 cancer model. (F–H) Capan-2 tumors were treated with PBS (F), engineered SL^lux (G), or SL^lux/ClyA (H).